The Intensive Medicines Monitoring Programme (IMMP) is a pharmacovigilance system in New Zealand focused on monitoring the safety of medicines after authorization.
IMMP approaches generate real-world safety insights using systematic follow-up and structured event reporting in routine clinical use. These findings complement clinical trial safety data by identifying rare, delayed, or population-specific risks that may not appear in pre-approval studies. Sponsors may use IMMP-type evidence to refine risk management plans and safety communications. Post-authorization surveillance strengthens benefitñrisk evaluation over time and supports regulatory decision-making.